Loading...

Derick H Lau, MD

Title(s)Professor Emeritus, Hematology and Oncology
SchoolUniversity of California, Davis
Address4501 X Street, #3016
CA 95817
Phone916-734-3772
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Phase I study of the halichondrin B analogue eribulin mesylate in combination with cisplatin in advanced solid tumors. Br J Cancer. 2014 Dec 09; 111(12):2268-74. Koczywas M, Frankel PH, Synold TW, Lenz HJ, Mortimer JE, El-Khoueiry AB, Gandara DR, Cristea MC, Chung VM, Lim D, Reckamp KL, Lau DH, Doyle LA, Ruel C, Carroll MI, Newman EM. PMID: 25349975.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    2. Quality of life among long-term survivors of head and neck cancer treated by intensity-modulated radiotherapy. JAMA Otolaryngol Head Neck Surg. 2014 Feb; 140(2):129-33. Chen AM, Daly ME, Farwell DG, Vazquez E, Courquin J, Lau DH, Purdy JA. PMID: 24337483.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    3. Phase I/II trial of pemetrexed plus nab-paclitaxel in advanced solid tumor patients with emphasis on non-small cell lung cancer. Invest New Drugs. 2013 Dec; 31(6):1587-91. Ho C, Davies AM, Sangha RS, Lau D, Lara P, Chew HK, Beckett L, Mack PC, Riess JW, Gandara DR. PMID: 24013936.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    4. A Pilot Study (SWOG S0429) of Weekly Cetuximab and Chest Radiotherapy for Poor-Risk Stage III Non-Small Cell Lung Cancer. Front Oncol. 2013; 3:219. Chen Y, Moon J, Pandya KJ, Lau DH, Kelly K, Hirsch FR, Gaspar LE, Redman M, Gandara DR. PMID: 24010120.
      View in: PubMed   Mentions:
    5. Feasibility and toxicity of concurrent chemoradiation for elderly patients with head and neck cancer. Am J Otolaryngol. 2013 Nov-Dec; 34(6):631-5. Daly ME, Lau DH, Farwell DG, Luu Q, Donald PJ, Chen AM. PMID: 23954137.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    6. Southwestern oncology group phase II trial (S0526) of pemetrexed in bronchioloalveolar carcinoma subtypes of advanced adenocarcinoma. Clin Lung Cancer. 2013 Jul; 14(4):351-5. Lau DH, Moon J, Davies AM, Sanborn RE, Hirsch FR, Franklin WA, Ruzich JC, Redman MW, Gandara DR. PMID: 23415808.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    7. Differential response rates to irradiation among patients with human papillomavirus positive and negative oropharyngeal cancer. Laryngoscope. 2013 Jan; 123(1):152-7. Chen AM, Li J, Beckett LA, Zhara T, Farwell G, Lau DH, Gandour-Edwards R, Vaughan AT, Purdy JA. PMID: 23008061.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    8. Brachial plexus-associated neuropathy after high-dose radiation therapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2012 Sep 01; 84(1):165-9. Chen AM, Hall WH, Li J, Beckett L, Farwell DG, Lau DH, Purdy JA. PMID: 22444998.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansPHPublic Health
    9. Intensity-modulated radiotherapy is associated with improved global quality of life among long-term survivors of head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2012 Sep 01; 84(1):170-5. Chen AM, Farwell DG, Luu Q, Vazquez EG, Lau DH, Purdy JA. PMID: 22300572.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    10. Intercalated erlotinib-docetaxel dosing schedules designed to achieve pharmacodynamic separation: results of a phase I/II trial. J Thorac Oncol. 2011 Dec; 6(12):2112-9. Sangha R, Davies AM, Lara PN, Mack PC, Beckett LA, Hesketh PJ, Lau D, Li T, Perkins N, Gandara DR. PMID: 21892109.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    11. A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium Study. Cancer Chemother Pharmacol. 2012 Mar; 69(3):835-43. Chao J, Synold TW, Morgan RJ, Kunos C, Longmate J, Lenz HJ, Lim D, Shibata S, Chung V, Stoller RG, Belani CP, Gandara DR, McNamara M, Gitlitz BJ, Lau DH, Ramalingam SS, Davies A, Espinoza-Delgado I, Newman EM, Yen Y. PMID: 22105720.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    12. Feasibility study of intra-patient sorafenib dose-escalation or re-escalation in patients with previously treated advanced solid tumors. Invest New Drugs. 2012 Oct; 30(5):2001-7. Semrad TJ, Eddings C, Pan CX, Lau DH, Gandara D, Beckett L, Lara PN. PMID: 22015991.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    13. Voice quality after organ-preservation therapy with definitive radiotherapy for laryngeal cancer. Head Neck. 2012 Jul; 34(7):943-8. Lau VH, Leonard RJ, Goodrich S, Luu Q, Farwell DG, Lau DH, Purdy JA, Chen AM. PMID: 22127963.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    14. Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial. Clin Lung Cancer. 2011 Jan; 12(1):33-7. Lara PN, Longmate J, Reckamp K, Gitlitz B, Argiris A, Ramalingam S, Belani CP, Mack PC, Lau DH, Koczywas M, Wright JJ, Shepherd FA, Leighl N, Gandara DR. PMID: 21273177.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    15. Radiation therapy in the management of head-and-neck cancer of unknown primary origin: how does the addition of concurrent chemotherapy affect the therapeutic ratio? Int J Radiat Oncol Biol Phys. 2011 Oct 01; 81(2):346-52. Chen AM, Farwell DG, Lau DH, Li BQ, Luu Q, Donald PJ. PMID: 20933340.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    16. Tobacco smoking during radiation therapy for head-and-neck cancer is associated with unfavorable outcome. Int J Radiat Oncol Biol Phys. 2011 Feb 01; 79(2):414-9. Chen AM, Chen LM, Vaughan A, Sreeraman R, Farwell DG, Luu Q, Lau DH, Stuart K, Purdy JA, Vijayakumar S. PMID: 20399030.
      View in: PubMed   Mentions: 47     Fields:    Translation:Humans
    17. Primary radiation therapy for head-and-neck cancer in the setting of human immunodeficiency virus. Int J Radiat Oncol Biol Phys. 2011 Jan 01; 79(1):60-4. Klein EA, Guiou M, Farwell DG, Luu Q, Lau DH, Stuart K, Vaughan A, Vijayakumar S, Chen AM. PMID: 20385454.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    18. Evaluating the role of prophylactic gastrostomy tube placement prior to definitive chemoradiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys. 2010 Nov 15; 78(4):1026-32. Chen AM, Li BQ, Lau DH, Farwell DG, Luu Q, Stuart K, Newman K, Purdy JA, Vijayakumar S. PMID: 20231073.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    19. Escalating weekly doses of cetuximab and correlation with skin toxicity: a phase I study. Invest New Drugs. 2011 Aug; 29(4):680-7. Ho C, Sangha R, Beckett L, Tanaka M, Lau DH, Eisen DB, Burich RA, Luciw P, Khan I, Mack PC, Gandara DR, Davies AM. PMID: 20148348.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    20. Late esophageal toxicity after radiation therapy for head and neck cancer. Head Neck. 2010 Feb; 32(2):178-83. Chen AM, Li BQ, Jennelle RL, Lau DH, Yang CC, Courquin J, Vijayakumar S, Purdy JA. PMID: 19536858.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    21. Clinical-dosimetric analysis of measures of dysphagia including gastrostomy-tube dependence among head and neck cancer patients treated definitively by intensity-modulated radiotherapy with concurrent chemotherapy. Radiat Oncol. 2009 Nov 12; 4:52. Li B, Li D, Lau DH, Farwell DG, Luu Q, Rocke DM, Newman K, Courquin J, Purdy JA, Chen AM. PMID: 19909531.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    22. LAS0811: from combinatorial chemistry to activation of antioxidant response element. J Biomed Biotechnol. 2009; 2009:420194. Zhu M, Baek H, Liu R, Song A, Lam K, Lau D. PMID: 19794825.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    23. Intermittent erlotinib in combination with pemetrexed: phase I schedules designed to achieve pharmacodynamic separation. J Thorac Oncol. 2009 Jul; 4(7):862-8. Davies AM, Ho C, Beckett L, Lau D, Scudder SA, Lara PN, Perkins N, Gandara DR. PMID: 19494788.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    24. A population-based clinical trial of irinotecan and Carboplatin. J Oncol. 2009; 2009:458528. Lau D, Huynh M, Johl J. PMID: 19404408.
      View in: PubMed   Mentions:
    25. Phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung cancer. J Clin Oncol. 2009 Mar 20; 27(9):1401-4. Chen G, Huynh M, Fehrenbacher L, West H, Lara PN, Yavorkovsky LL, Russin M, Goldstein D, Gandara D, Lau D. PMID: 19204194.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    26. A novel small molecule, LAS-0811, inhibits alcohol-induced apoptosis in VL-17A cells. Biochem Biophys Res Commun. 2009 Feb 20; 379(4):876-81. Kim TH, Venugopal SK, Zhu M, Wang SS, Lau D, Lam KS, Clemens DL, Zern MA. PMID: 19133235.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    27. Population-based phase I trial of irinotecan and epirubicin. Am J Clin Oncol. 2008 Jun; 31(3):226-30. Lau D, Johl J, Huynh M, Davies A, Tanaka M, Lara P, Gandara D. PMID: 18525299.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    28. Adjuvant treatment of stage IB NSCLC: the problem of stage subset heterogeneity. Oncology (Williston Park). 2008 Apr 30; 22(5):511-6; discussion 516, 521-3. Calhoun R, Jablons D, Lau D, Gandara DR. PMID: 18533401.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    29. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol. 2008 May 20; 26(15):2450-6. Kelly K, Chansky K, Gaspar LE, Albain KS, Jett J, Ung YC, Lau DH, Crowley JJ, Gandara DR. PMID: 18378568.
      View in: PubMed   Mentions: 150     Fields:    Translation:HumansCTClinical Trials
    30. Mediastinoscopy might not be necessary in patients with non-small cell lung cancer with mediastinal lymph nodes having a maximum standardized uptake value of less than 5.3. J Thorac Cardiovasc Surg. 2008 Mar; 135(3):615-9. Lee BE, Redwine J, Foster C, Abella E, Lown T, Lau D, Follette D. PMID: 18329480.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    31. Chemotherapy for brain metastases in small-cell lung cancer. Clin Lung Cancer. 2008 Jan; 9(1):35-8. Chen G, Huynh M, Chen A, Fehrenbacher L, Gandara D, Lau D. PMID: 18282356.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    32. The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study. J Thorac Oncol. 2008 Jan; 3(1):68-74. Davies AM, Ruel C, Lara PN, Lau DH, Gumerlock PH, Bold R, Shibata S, Lenz HJ, Schenkein DP, Gandara DR. PMID: 18166843.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    33. Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer. J Thorac Oncol. 2007 Dec; 2(12):1112-6. Davies AM, Ho C, Metzger AS, Beckett LA, Christensen S, Tanaka M, Lara PN, Lau DH, Gandara DR. PMID: 18090584.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    34. Erlotinib and vinorelbine in advanced malignant solid tumors: a phase I study. Invest New Drugs. 2007 Aug; 25(4):351-5. Davies AM, Ho C, Hesketh PJ, Beckett LA, Lara PN, Lau DH, Gandara DR. PMID: 17440682.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    35. Advances in positron emission tomography technology have increased the need for surgical staging in non-small cell lung cancer. J Thorac Cardiovasc Surg. 2007 Mar; 133(3):746-52. Lee BE, von Haag D, Lown T, Lau D, Calhoun R, Follette D. PMID: 17320577.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    36. A phase II study of paclitaxel, carboplatin, and radiation with or without surgery for esophageal cancer. J Thorac Oncol. 2007 Feb; 2(2):153-7. Wang H, Ryu J, Gandara D, Bold RJ, Urayama S, Tanaka M, Goldberg Z, Follette D, Narayan S, Lau D. PMID: 17410032.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    37. Epidermal growth factor receptor inhibitors plus chemotherapy in non-small-cell lung cancer: biologic rationale for combination strategies. Clin Lung Cancer. 2007 Feb; 8 Suppl 2:S61-7. Gandara DR, Davies AM, Gautschi O, Mack PC, Lau DH, Lara PN, Hirsch FR. PMID: 17382026.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimals
    38. Phase II study of consolidation paclitaxel after concurrent chemoradiation in poor-risk stage III non-small-cell lung cancer: SWOG S9712. J Clin Oncol. 2006 Nov 20; 24(33):5242-6. Davies AM, Chansky K, Lau DH, Leigh BR, Gaspar LE, Weiss GR, Wozniak AJ, Crowley JJ, Gandara DR. PMID: 17114656.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    39. Radiographic imaging of bronchioloalveolar carcinoma: screening, patterns of presentation and response assessment. J Thorac Oncol. 2006 Nov; 1(9 Suppl):S20-6. Gandara DR, Aberle D, Lau D, Jett J, Akhurst T, Heelan R, Mulshine J, Berg C, Patz EF. PMID: 17409997.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansPHPublic Health
    40. Sequential vinorelbine and docetaxel in advanced non-small cell lung cancer patients age 70 and older and/or with a performance status of 2: a phase II trial of the Southwest Oncology Group (S0027). J Thorac Oncol. 2006 Jul; 1(6):537-44. Hesketh PJ, Chansky K, Lau DH, Doroshow JH, Moinpour CM, Chapman RA, Goodwin JW, Gross HM, Crowley JJ, Gandara DR. PMID: 17409914.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    41. Peptide ligands targeting integrin alpha3beta1 in non-small cell lung cancer. Lung Cancer. 2006 Jun; 52(3):291-7. Lau D, Guo L, Liu R, Marik J, Lam K. PMID: 16635537.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    42. Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126. J Clin Oncol. 2006 Apr 20; 24(12):1807-13. West HL, Franklin WA, McCoy J, Gumerlock PH, Vance R, Lau DH, Chansky K, Crowley JJ, Gandara DR. PMID: 16622257.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCTClinical Trials
    43. Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial. J Thorac Oncol. 2006 Feb; 1(2):126-34. Lara PN, Koczywas M, Quinn DI, Lenz HJ, Davies AM, Lau DH, Gumerlock PH, Longmate J, Doroshow JH, Schenkein D, Kashala O, Gandara DR. PMID: 17409841.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    44. Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003. J Clin Oncol. 2005 Dec 20; 23(36):9097-104. Williamson SK, Crowley JJ, Lara PN, McCoy J, Lau DH, Tucker RW, Mills GM, Gandara DR. PMID: 16361616.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansCTClinical Trials
    45. Integration of novel therapeutics into combined modality therapy of locally advanced non-small cell lung cancer. Clin Cancer Res. 2005 Jul 01; 11(13 Pt 2):5057s-5062s. Gandara D, Narayan S, Lara PN, Goldberg Z, Davies A, Lau DH, Mack P, Gumerlock P, Vijayakumar S. PMID: 16000614.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    46. Thrombotic thrombocytopenic purpura associated with quetiapine. Ann Pharmacother. 2005 Jul-Aug; 39(7-8):1346-8. Huynh M, Chee K, Lau DH. PMID: 15914516.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    47. Identification of novel targeting peptides for human ovarian cancer cells using "one-bead one-compound" combinatorial libraries. Mol Cancer Ther. 2005 May; 4(5):806-13. Aina OH, Marik J, Liu R, Lau DH, Lam KS. PMID: 15897245.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCells
    48. Complete response of brain metastases to irinotecan-based chemotherapy. J Clin Neurosci. 2005 Apr; 12(3):242-5. Chou R, Chen A, Lau D. PMID: 15851073.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    49. Computer-assisted image analysis of bronchioloalveolar carcinoma. Clin Lung Cancer. 2005 Mar; 6(5):281-6. Lau D, Seibert A, Gandara D, Laptalo L, Geraghty E, Coulon C. PMID: 15845178.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    50. Intermittent dosing of the farnesyl transferase inhibitor tipifarnib (R115777) in advanced malignant solid tumors: a phase I California Cancer Consortium Trial. Anticancer Drugs. 2005 Mar; 16(3):317-21. Lara PN, Law LY, Wright JJ, Frankel P, Twardowski P, Lenz HJ, Lau DH, Kawaguchi T, Gumerlock PH, Doroshow JH, Gandara DR. PMID: 15711184.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCellsCTClinical Trials
    51. Is inhibition of cancer angiogenesis and growth by paclitaxel schedule dependent? Anticancer Drugs. 2004 Oct; 15(9):871-5. Lau D, Guo L, Gandara D, Young LJ, Xue L. PMID: 15457127.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    52. Novel peptide ligands for integrin alpha 4 beta 1 overexpressed in cancer cells. Mol Cancer Ther. 2004 Oct; 3(10):1329-34. Mikawa M, Wang H, Guo L, Liu R, Marik J, Takada Y, Lam K, Lau D. PMID: 15486200.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimalsCells
    53. An evaluation of barriers to accrual in the era of legislation requiring insurance coverage of cancer clinical trial costs in California. Cancer J. 2004 Sep-Oct; 10(5):294-300. Martel CL, Li Y, Beckett L, Chew H, Christensen S, Davies A, Lam KS, Lau DH, Meyers FJ, O'donnell RT, Richman C, Scudder S, Tanaka M, Tuscano J, Welborn J, Wun T, Gandara DR, Lara PN. PMID: 15530258.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    54. Gemcitabine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: a phase II California cancer consortium trial. Clin Lung Cancer. 2004 Sep; 6(2):102-7. Lara PN, Gumerlock PH, Mack PC, Lau DH, Gandour-Edwards R, Edelman MJ, Albain KS, Law LY, Longmate J, Frankel P, Reddy GP, Israel V, Doroshow JH, Gandara DR. PMID: 15476595.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    55. Bronchioloalveolar carcinoma: a model for investigating the biology of epidermal growth factor receptor inhibition. Clin Cancer Res. 2004 Jun 15; 10(12 Pt 2):4205s-4209s. Gandara DR, West H, Chansky K, Davies AM, Lau DH, Crowley J, Gumerlock PH, Hirsch FR, Franklin WA. PMID: 15217959.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    56. Enhancement of radiotherapy with DNA topoisomerase I-targeted drugs. Crit Rev Oncol Hematol. 2004 May; 50(2):111-9. Chen AY, Chou R, Shih SJ, Lau D, Gandara D. PMID: 15157660.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimals
    57. Treatment of extensive small cell lung cancer. Hematol Oncol Clin North Am. 2004 Apr; 18(2):373-85. Davies AM, Lara PN, Lau DH, Gandara DR. PMID: 15094177.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    58. Predictive molecular markers: has the time come for routine use in lung cancer? J Natl Compr Canc Netw. 2004 Mar; 2(2):125-31. Davies AM, Mack PC, Lara PN, Lau DH, Danenberg K, Gumerlock PH, Gandara DR. PMID: 19777702.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    59. Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial. Clin Lung Cancer. 2004 Jan; 5(4):231-6. Lara PN, Laptalo L, Longmate J, Lau DH, Gandour-Edwards R, Gumerlock PH, Doroshow JH, Gandara DR. PMID: 14967075.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    60. Resection of multifocal non-small cell lung cancer when the bronchioloalveolar subtype is involved. J Thorac Cardiovasc Surg. 2003 Nov; 126(5):1597-602. Roberts PF, Straznicka M, Lara PN, Lau DH, Follette DM, Gandara DR, Benfield JR. PMID: 14666039.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    61. Tirapazamine plus carboplatin and paclitaxel in advanced malignant solid tumors: a california cancer consortium phase I and molecular correlative study. Clin Cancer Res. 2003 Oct 01; 9(12):4356-62. Lara PN, Frankel P, Mack PC, Gumerlock PH, Galvin I, Martel CL, Longmate J, Doroshow JH, Lenz HJ, Lau DH, Gandara DR. PMID: 14555506.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    62. Magnetization of large polystyrene peptide beads for capturing and expanding cancer cells. Journal of Magnetism and Magnetic Materials. 2003 Aug 1; 264(2-3):153-157. Jan Mari´k, Derick H Lau, Aimin Song, Xiaobing Wang, Ruiwu Liu, Kit S Lam. .
      View in: Publisher Site   Mentions:
    63. Identification of lung micrometastatic tumor foci in nude mice with implanted tumor using laser capture microdissection and PCR-single-strand conformation polymorphism. Di Yi Jun Yi Da Xue Xue Bao. 2003 Jul; 23(7):725-7. Guo LL, Guo Y, Xiao S, Lau D. PMID: 12865233.
      View in: PubMed   Mentions:    Fields:    Translation:Animals
    64. Population-based maximum tolerated dose of irinotecan and carboplatin. Oncology (Williston Park). 2003 Jul; 17(7 Suppl 7):11-6. Wild CA, Wang SE, Gandara DR, Lara PN, Meyers FJ, Tanaka M, Houston J, Lauder J, Lau DH. PMID: 12886868.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    65. SPR1. An early molecular marker for bronchial carcinogenesis. Methods Mol Med. 2003; 75:397-403. Lau D, Guo L, Chan A, Wu R. PMID: 12407755.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    66. Antisense oligonucleotides in the treatment of non-small-cell lung cancer. Clin Lung Cancer. 2003 Jan; 4 Suppl 2:S68-73. Davies AM, Gandara DR, Lara PN, Mack PC, Lau DH, Gumerlock PH. PMID: 14720340.
      View in: PubMed   Mentions: 3     Fields:    
    67. Phase I trial of gemcitabine and paclitaxel in advanced solid tumors. Cancer Invest. 2003; 21(1):7-13. Lim N, Lara PN, Lau DH, Edelman MJ, Tanaka M, al-Jazayrly G, Houston J, Lauder I, Gandara DR. PMID: 12643004.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    68. Unfavorable therapeutic index of cisplatin/gemcitabine/vinorelbine in advanced non-small-cell lung cancer. Clin Lung Cancer. 2002 Jul; 4(1):47-51. Hesketh PJ, Nauman CJ, Hesketh AM, LaPointe J, Fogarty K, Oo TH, Lau DH, Edelman MJ, Gandara DR. PMID: 14653876.
      View in: PubMed   Mentions:    Fields:    
    69. Current and future therapeutic approaches in locally advanced (stage III) non-small cell lung cancer. Semin Oncol. 2002 Jun; 29(3 Suppl 12):10-6. Davies A, Gandara DR, Lara P, Goldberg Z, Roberts P, Lau D. PMID: 12170446.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    70. Sequential combination chemotherapy in patients with advanced nonsmall cell lung carcinoma. Carboplatin and gemcitabine followed by paclitaxel. Cancer. 2002 May 15; 94(10):2797-8; author reply 2798-9. De Castro J, Feliu J, Casado E, Ordoñez A, González Barón M. PMID: 12173351.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    71. Concurrent chemoradiation strategies in the management of unresectable stage III non-small-cell lung cancer. Clin Lung Cancer. 2002 May; 3 Suppl 2:S42-8. Lara PN, Goldberg Z, Davies A, Lau DH, Gandara DR. PMID: 14720347.
      View in: PubMed   Mentions:    Fields:    
    72. Identifying peptide ligands for cell surface receptors using cell-growth-on-bead assay and one-bead one-compound combinatorial library. Biotechnology Letters. 2002 Mar 1; 24(6):497-500. Derick H. Lau, Linlang Guo, Ruiwu Liu, Aimin Song, Chunkui Shao, Kit S. Lam. .
      View in: Publisher Site   Mentions:
    73. Tirapazamine: prototype for a novel class of therapeutic agents targeting tumor hypoxia. Semin Oncol. 2002 Feb; 29(1 Suppl 4):102-9. Gandara DR, Lara PN, Goldberg Z, Le QT, Mack PC, Lau DH, Gumerlock PH. PMID: 11894020.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    74. Contributions of mouse biology to breast cancer research. Comp Med. 2002 Feb; 52(1):12-31. Cardiff RD, Bern HA, Faulkin LJ, Daniel CW, Smith GH, Young LJ, Medina D, Gardner MB, Wellings SR, Shyamala G, Guzman RC, Rajkumar L, Yang J, Thordarson G, Nandi S, MacLeod CL, Oshima RG, Man AK, Sawai ET, Gregg JP, Cheung AT, Lau DH. PMID: 11900409.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimals
    75. Non-small-cell lung cancer progression after first-line chemotherapy. Curr Treat Options Oncol. 2002 Feb; 3(1):53-8. Lara PN, Lau DH, Gandara DR. PMID: 12057087.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    76. Premedication strategy for weekly paclitaxel. Cancer Invest. 2002; 20(5-6):666-72. Quock J, Dea G, Tanaka M, Gandara D, Lara P, Lau D. PMID: 12197222.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    77. Molecular-clinical correlative studies in non-small cell lung cancer: application of a three-tiered approach. Lung Cancer. 2001 Dec; 34 Suppl 3:S75-80. Gandara DR, Lara PN, Lau DH, Mack P, Gumerlock PH. PMID: 11740998.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    78. Evaluation of minimally invasive surgical staging for esophageal cancer. Am J Surg. 2001 Dec; 182(6):702-6. Nguyen NT, Roberts PF, Follette DM, Lau D, Lee J, Urayama S, Wolfe BM, Goodnight JE. PMID: 11839342.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    79. Sequential combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: carboplatin and gemcitabine followed by paclitaxel. Cancer. 2001 Jul 01; 92(1):146-52. Edelman MJ, Gandara DR, Lau DH, Lara P, Lauder IJ, Tracy D. PMID: 11443620.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    80. Activity of high-dose toremifene plus cisplatin in platinum-treated non-small-cell lung cancer: a phase II California Cancer Consortium Trial. Cancer Chemother Pharmacol. 2001 Jul; 48(1):22-8. Lara PN, Gandara DR, Longmate J, Gumerlock PH, Lau DH, Edelman MJ, Gandour-Edwards R, Mack PC, Israel V, Raschko J, Frankel P, Perez EA, Lenz HJ, Doroshow JH. PMID: 11488520.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    81. Integration of new chemotherapeutic agents into chemoradiotherapy for stage III non--small cell lung cancer: focus on docetaxel. Semin Oncol. 2001 Jun; 28(3 Suppl 9):26-32. Gandara DR, Lara PN, Goldberg Z, Lau DH. PMID: 11441412.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    82. Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. J Clin Oncol. 2001 Mar 15; 19(6):1728-33. Lara PN, Higdon R, Lim N, Kwan K, Tanaka M, Lau DH, Wun T, Welborn J, Meyers FJ, Christensen S, O'Donnell R, Richman C, Scudder SA, Tuscano J, Gandara DR, Lam KS. PMID: 11251003.
      View in: PubMed   Mentions: 162     Fields:    Translation:Humans
    83. Gemcitabine in combination with new platinum compounds: an update. Oncology (Williston Park). 2001 Mar; 15(3 Suppl 6):13-7. Gandara DR, Edelman MJ, Lara PN, Lau DH. PMID: 11301843.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    84. Neoadjuvant therapy for non-small cell lung cancer. Anticancer Drugs. 2001 Feb; 12 Suppl 1:S5-9. Gandara DR, Lara PN, Goldberg Z, Roberts P, Lau DH. PMID: 11340902.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    85. Twice-weekly paclitaxel and weekly carboplatin with concurrent thoracic radiation followed by carboplatin/paclitaxel consolidation for stage III non-small-cell lung cancer: a California Cancer Consortium phase II trial. J Clin Oncol. 2001 Jan 15; 19(2):442-7. Lau D, Leigh B, Gandara D, Edelman M, Morgan R, Israel V, Lara P, Wilder R, Ryu J, Doroshow J. PMID: 11208837.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    86. Quantitative analysis of angiogenesis using confocal laser scanning microscopy. Angiogenesis. 2001; 4(3):187-91. Guo L, Burke P, Lo SH, Gandour-Edwards R, Lau D. PMID: 11911016.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimals
    87. Evolution of combined modality therapy for stage III non-small-cell lung cancer. Oncology (Williston Park). 2000 Jul; 14(7 Suppl 5):35-41. Gandara DR, Edelman M, Lara P, Roberts P, Leigh B. PMID: 10981289.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    88. Gemcitabine/carboplatin combination regimens: importance of dose schedule. Oncology (Williston Park). 2000 Jul; 14(7 Suppl 4):26-30. Gandara DR, Lau DH, Lara PN, Edelman MJ. PMID: 10960942.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    89. Expression and regulation of a molecular marker, SPR1, in multistep bronchial carcinogenesis. Am J Respir Cell Mol Biol. 2000 Jan; 22(1):92-6. Lau D, Xue L, Hu R, Liaw T, Wu R, Reddy S. PMID: 10615070.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    90. Emerging role of docetaxel (Taxotere) in advanced non-small cell lung cancer. Semin Oncol. 1999 Jun; 26(3 Suppl 10):3-7. Gandara DR, Edelman MJ, Lau D. PMID: 10437743.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    91. Concurrent twice-weekly paclitaxel and thoracic irradiation for stage III non-small cell lung cancer. Semin Radiat Oncol. 1999 Apr; 9(2 Suppl 1):117-20. Lau D, Ryu J, Gandara D, Morgan R, Doroshow J, Wilder R, Leigh B. PMID: 10210550.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    92. Paclitaxel (Taxol): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer. Cancer Biother Radiopharm. 1999 Feb; 14(1):31-6. Lau DH, Xue L, Young LJ, Burke PA, Cheung AT. PMID: 10850285.
      View in: PubMed   Mentions: 30     Fields:    Translation:Animals
    93. Treatment of poor-prognosis extensive disease small-cell lung cancer with an all-oral regimen of etoposide and cyclophosphamide - a Southwest Oncology Group clinical and pharmacokinetic study. Cancer Chemother Pharmacol. 1999; 44(6):461-8. Grunberg SM, Crowley J, Hande KR, Giroux D, Munshi N, Lau DH, Schroder LE, Zangmeister MH, Balcerzak SP, Hynes HE, Gandara DR. PMID: 10550566.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    94. Severe esophageal toxicity after thoracic radiation therapy for lung cancer associated with the human immunodeficiency virus: a case report and review of the literature. Am J Clin Oncol. 1998 Oct; 21(5):479-81. Leigh BR, Lau DH. PMID: 9781604.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansPHPublic Health
    95. Southwest Oncology Group phase II trial of concurrent carboplatin, etoposide, and radiation for poor-risk stage III non-small-cell lung cancer. J Clin Oncol. 1998 Sep; 16(9):3078-81. Lau DH, Crowley JJ, Gandara DR, Hazuka MB, Albain KS, Leigh B, Fletcher WS, Lanier KS, Keiser WL, Livingston RB. PMID: 9738578.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    96. A small proline-rich protein, spr1: specific marker for squamous lung carcinoma. Lung Cancer. 1998 Apr; 20(1):25-30. Hu R, Wu R, Deng J, Lau D. PMID: 9699184.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    97. Phase I trial of edatrexate plus carboplatin in advanced solid tumors: amelioration of dose-limiting mucositis by ice chip cryotherapy. Invest New Drugs. 1998; 16(1):69-75. Edelman MJ, Gandara DR, Perez EA, Lau D, Lauder I, Turrell C, Uhrich M, Meyers F. PMID: 9740546.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    98. High-dose toremifene as a cisplatin modulator in metastatic non-small cell lung cancer: targeted plasma levels are achievable clinically. Cancer Chemother Pharmacol. 1998; 42(6):504-8. Lara PN, Gandara DR, Wurz GT, Lau D, Uhrich M, Turrell C, Raschko J, Edelman MJ, Synold T, Doroshow J, Muggia F, Perez EA, DeGregorio M. PMID: 9788578.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    99. Twice-weekly paclitaxel and radiation for stage III non-small cell lung cancer. Semin Oncol. 1997 Aug; 24(4 Suppl 12):S12-106-S12-109. Lau DH, Ryu JK, Gandara DR, Morgan R, Doroshow J, Wilder R, Leigh B. PMID: 9331132.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    100. Chemoradiotherapy for poor-risk stage III non-small cell lung cancer. Semin Oncol. 1997 Aug; 24(4 Suppl 12):S12-110-S12-112. Lau DH, Ryu JK, Gandara DR. PMID: 9331133.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    101. Clonal origin of multiple lung cancers: K-ras and p53 mutations determined by nonradioisotopic single-strand conformation polymorphism analysis. Diagn Mol Pathol. 1997 Aug; 6(4):179-84. Lau DH, Yang B, Hu R, Benfield JR. PMID: 9360838.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    102. Concurrent carboplatin, etoposide and thoracic radiation for poor-risk stage III non-small-cell lung carcinoma: a pilot study. Int J Radiat Oncol Biol Phys. 1997 Apr 01; 38(1):157-61. Lau DH, Ryu JK, Gandara DR, Rosenthal SA. PMID: 9212018.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    103. Phase II trial of edatrexate plus carboplatin in metastatic non-small-cell lung cancer: a Southwest Oncology Group study. Cancer Chemother Pharmacol. 1997; 41(1):75-8. Gandara DR, Edelman MJ, Crowley JJ, Lau DH, Livingston RB. PMID: 9443617.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    104. Phase I study of paclitaxel with oral etoposide in advanced solid tumors. Cancer J Sci Am. 1996 Sep-Oct; 2(5):286-90. Perez EA, Coe T, Turrell C, Lau D, Campbell D, Gandara D. PMID: 9166546.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    105. Differential single- versus double-strand DNA breakage produced by doxorubicin and its morpholinyl analogues. Cancer Chemother Pharmacol. 1996; 38(3):210-6. Duran GE, Lau DH, Lewis AD, Kühl JS, Bämmler TK, Sikic BI. PMID: 8646794.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    106. Loss of nm23 and Alu DNA in human lung cancer propagated in nude mice. Cancer Lett. 1995 Nov 06; 97(2):163-8. Lau DH, Lu D, Hammond WG, Schmid CW, Benfield JR. PMID: 7497458.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    107. Metabolic conversion of methoxymorpholinyl doxorubicin: from a DNA strand breaker to a DNA cross-linker. Br J Cancer. 1994 Jul; 70(1):79-84. Lau DH, Duran GE, Lewis AD, Sikic BI. PMID: 8018545.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    108. Early manifestation of thrombotic thrombocytopenic purpura. Am J Med. 1993 Nov; 95(5):544-5. Lau DH, Wun T. PMID: 8238072.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    109. Characterization of covalent DNA binding of morpholino and cyanomorpholino derivatives of doxorubicin. J Natl Cancer Inst. 1992 Oct 21; 84(20):1587-92. Lau DH, Durán GE, Sikic BI. PMID: 1404452.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    110. Role of cytochrome P-450 from the human CYP3A gene family in the potentiation of morpholino doxorubicin by human liver microsomes. Cancer Res. 1992 Aug 15; 52(16):4379-84. Lewis AD, Lau DH, Durán GE, Wolf CR, Sikic BI. PMID: 1643634.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimalsCells
    111. Sensitization of drug resistant human ovarian cancer cells to cyanomorpholino doxorubicin (MRA-CN) by modulation of glutathione metabolism. Int J Radiat Oncol Biol Phys. 1992; 22(4):821-4. Lewis AD, Durán GE, Lau DH, Sikic BI. PMID: 1544857.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    112. Multifactorial mechanisms associated with broad cross-resistance of ovarian carcinoma cells selected by cyanomorpholino doxorubicin. Cancer Res. 1991 Oct 01; 51(19):5181-7. Lau DH, Lewis AD, Ehsan MN, Sikic BI. PMID: 1717140.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCells
    113. Paradoxical increase in DNA cross-linking in a human ovarian carcinoma cell line resistant to cyanomorpholino doxorubicin. Cancer Res. 1990 Jul 01; 50(13):4056-60. Lau DH, Ross KL, Sikic BI. PMID: 2162251.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    114. Association of DNA cross-linking with potentiation of the morpholino derivative of doxorubicin by human liver microsomes. J Natl Cancer Inst. 1989 Jul 05; 81(13):1034-8. Lau DH, Lewis AD, Sikic BI. PMID: 2733045.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    115. Uptake, metabolism and efflux of l-alpha-acetylmethadol (LAAM) by rat lung tissue. J Pharmacol Exp Ther. 1978 Jul; 206(1):143-50. Lau DH, Henderson GL. PMID: 660544.
      View in: PubMed   Mentions:    Fields:    Translation:Animals
    116. Plasma l-alpha-Acetylmethadol (LAAM) after acute and chronic administration. Clin Pharmacol Ther. 1977 Jan; 21(1):16-25. Henderson GL, Wilson BK, Lau DH. PMID: 832446.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    117. Comparative study on the derivatization of l-alpha-acetyl-methadol metabolites for electron capture gas-liquid chromatography. J Chromatogr. 1976 Dec 22; 129:329-38. Lau DH, Henderson GL. PMID: 1002792.
      View in: PubMed   Mentions:    Fields:    Translation:Humans